2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS) - Beyond the Abstract

The Phase 3 ATLAS trial of primary chemoablation using UGN-102, a reverse thermal gel containing mitomycin, provides important data about a potential nonsurgical alternative therapy for patients diagnosed with low grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). This form of urothelial malignancy affects over 80,000 Americans annually, recurs commonly, and is currently managed by repetitive transurethral resection of bladder tumor (TURBT).

The advanced age and significant comorbidities encountered in this patient population make surgery a suboptimal strategy for many patients due to procedure and anesthesia related risks. In ATLAS UGN-102 +/- subsequent TURBT was associated with a 55% reduction of risk for recurrence, progression, or death compared to TURBT monotherapy. The encouraging data reported by Prasad and colleagues provide further support for the development of primary non-surgical therapy for NMIBC.

Written by: Sandip M Prasad,1 William C Huang,2 Neal D Shore,3 Brian Hu,4 Marc Bjurlin,5 Gordon Brown,6 Pencho Genov,7 Dimitar Shishkov,8 Alexandre Khuskivadze,9 Tosho Ganev,10 Dobri Marchev,11 Igor Orlov,12 Evgeny Kopyltsov,13 Vadim Zubarev,14 Alexander Nosov,15 Dmitrii Komlev,16 Brent Burger,17 Sunil Raju,17 Andrew Meads,17 Mark Schoenberg18

  1. Morristown Medical Center/Atlantic Health System and Garden State Urology, Morristown, New Jersey.
  2. NYU Langone Urology Associates, New York, New York.
  3. Carolina Urologic Research Center, Myrtle Beach, South Carolina.
  4. The Department of Urology, Loma Linda University, Loma Linda, California.
  5. The Department of Urology, University of North Carolina, Chapel Hill, North Carolina.
  6. New Jersey Urology, Cherry Hill, New Jersey.
  7. Department of Urology, University Multiprofile Hospital for Active Treatment "Kanev," Ruse, Bulgaria.
  8. Department of Urology, University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria.
  9. Urology Department, LTD Gidmedi, Tbilisi, Georgia.
  10. Urology Clinic, Multiprofile Hospital for Active Treatment "Sveta Anna," Varna, Bulgaria.
  11. Department of Urology Multiprofile Hospital for Active Treatment-Shumen, Shumen, Bulgaria.
  12. Department of Urology, St Luka Clinical Hospital, Saint Petersburg, Russia.
  13. Department of Urology and Oncology, Clinical Oncology Center, Omsk, Russia.
  14. Department of Urology, Medical and Sanitary Unit 70 of Passazhiravtotrans, Saint Petersburg, Russia.
  15. Oncourology Department, NN Petrov National Medical Research Center of Oncology, Leningrad, Russia.
  16. Medical Center for Diagnostics and Prevention Plus, Yaroslavl, Russia.
  17. UroGen Pharma, Princeton, New Jersey.
  18. The Department of Urology, The Albert Einstein College of Medicine & The Montefiore Medical Center, Bronx, New York.
Read the Abstract